Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study

Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study

(2018) Jun Ishigooka et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia

(2017) Jun Ishigooka et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia

(2016) John M. Kane et al.   SCHIZOPHRENIA RESEARCH

Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies

(2016) Christoph U. Correll et al.   SCHIZOPHRENIA RESEARCH

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial

(2015) Christoph U. Correll et al.   AMERICAN JOURNAL OF PSYCHIATRY

A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia

(2015) John M. Kane et al.   SCHIZOPHRENIA RESEARCH

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

(2010) C.U. Correll   EUROPEAN PSYCHIATRY

Akathisia: An Updated Review Focusing on Second-Generation Antipsychotics

(2009) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHIATRY